WallStreetZenWallStreetZen

NASDAQ: QTTB
Q32 Bio Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their QTTB stock forecasts and price targets.

Forecast return on equity

Is QTTB forecast to generate an efficient return?

Insufficient data to display

Forecast return on assets

Is QTTB forecast to generate an efficient return on assets?

Company
-104.34%
Industry
26.78%
QTTB is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

QTTB earnings per share forecast

What is QTTB's earnings per share in the next 2 years based on estimates from 4 analysts?

Avg 1 year Forecast
-$2.65
Avg 2 year Forecast
-$4.90

QTTB revenue forecast

What is QTTB's revenue in the next 2 years based on estimates from 4 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0

QTTB vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
QTTB$3.60N/AN/A
INMB$1.63N/AN/A
PASG$14.28$34.50+141.60%Strong Buy
KZR$6.20$6.00-3.23%Hold
ANEB$1.04N/AN/A
View Top Biotech Stocks

Q32 Bio Stock Forecast FAQ

What is QTTB's earnings growth forecast for 2026-2027?

(NASDAQ: QTTB) Q32 Bio's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 203.83%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 3,218.54%.

Q32 Bio's earnings in 2026 is -$42,098,000.On average, 4 Wall Street analysts forecast QTTB's earnings for 2026 to be -$32,618,837, with the lowest QTTB earnings forecast at -$49,052,530, and the highest QTTB earnings forecast at -$14,599,114.

In 2027, QTTB is forecast to generate -$60,292,555 in earnings, with the lowest earnings forecast at -$61,738,317 and the highest earnings forecast at -$57,983,028.

If you're new to stock investing, here's how to buy Q32 Bio stock.

What is QTTB's revenue growth forecast for 2026-2027?

(NASDAQ: QTTB) Q32 Bio's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 11,869.46%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 1,514%.

Q32 Bio's revenue in 2026 is $0.On average, 4 Wall Street analysts forecast QTTB's revenue for 2026 to be $0, with the lowest QTTB revenue forecast at $0, and the highest QTTB revenue forecast at $0.

In 2027, QTTB is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is QTTB's forecast return on assets (ROA) for 2026-2027?

(NASDAQ: QTTB) forecast ROA is -104.34%, which is lower than the forecast US Biotechnology industry average of 26.78%.

What is QTTB's Earnings Per Share (EPS) forecast for 2026-2027?

(NASDAQ: QTTB) Q32 Bio's current Earnings Per Share (EPS) is -$3.39. On average, analysts forecast that QTTB's EPS will be -$2.65 for 2026, with the lowest EPS forecast at -$3.99, and the highest EPS forecast at -$1.19. In 2027, QTTB's EPS is forecast to hit -$4.90 (min: -$5.02, max: -$4.71).

What is QTTB's forecast return on equity (ROE) for 2026-2027?

(NASDAQ: QTTB) forecast ROE is N/A, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.